Alterity Therapeutics Limited (ATHE)

Market Cap	18.30M
Revenue (ttm)	2.68M
Net Income (ttm)	-12.76M
Shares Out	5.32B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,482
Open	2.060
Previous Close	2.100
Day's Range	2.050 - 2.252
52-Week Range	1.000 - 3.190
Beta	0.68
Analysts	Strong Buy
Price Target	6.00 (+172.73%)
Earnings Date	Feb 15, 2025

About ATHE

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: ATHE
• Website: https://alteritytherapeutics.com

Financial Performance

In 2024, Alterity Therapeutics's revenue was 4.02 million, an increase of 2.63% compared to the previous year's 3.92 million. Losses were -19.12 million, 38.5% more than in 2023.

Financial numbers in AUD

Analyst Forecast

According to 2 analysts, the average rating for ATHE stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 172.73% from the latest price.

Price Target

$6.0

(172.73% upside)

Analyst Consensus: Strong Buy